Where Does the Demand for the Billion-Dollar Cancer Early Screening Market Lie? BGI Genomics and DiAn Diagnostics Jointly Decode the Opportunities
In China, approximately 80% of cancer cases are diagnosed at an advanced stage, meaning that clinical observations capture only the tip of the iceberg in the course of cancer development. Early diagnosis, early detection, and early treatment represent the optimal solution.The Market for Early Cancer Screening Holds Enormous Potential, making it a research and development direction that has long been highly favored by companies both domestically and internationally. According to data cited in a Guosen Securities research report, the global NGS oncology market is projected to grow at a compound annual growth rate (CAGR) of 27%, reaching $75 billion by 2035, driven by the accelerated expansion of tumor testing applications and increased coverage among paying populations. Among these segments, early cancer screening represents the largest share, with an estimated CAGR of 75% and a target population coverage of 150 million individuals.
In this context, byVCBeat、VB100、EggshellResearch InstituteHosted by，Early Screening NetworkCo-organizerofThe 5th Future Healthcare Top 100 Conference·Early Cancer Screening Forumscheduled forAfternoon of April 18, 2021, exploring how to harness the power of scientific research translation to effectively commercialize products, leverage technology to empower precision diagnosis and treatment, and build a closed-loop internet-based diagnostic ecosystem. We will invite renowned industry experts to jointly explore new technologies, developments, and trends in the tumor early screening sector, and discuss emerging opportunities in this billion-dollar blue-ocean market.
Guest:Zhou Quan| Managing Director, Legend Capital
Topic: Investment Hotspots and Value Amid Industry Leapfrogging
Over the past two years, the primary market for early cancer screening has witnessed massive financing rounds, while the secondary market has seen soaring valuations. As cancer assumes an increasingly significant burden in the spectrum of human diseases, driven by technological leaps and regulatory innovations, the early cancer screening industry has demonstrated strong capital attraction.Among the 16 cancer early screening companies that secured financing in 2020, 11 raised over RMB 100 million. In July 2020, New Horizon Health completed its final pre-IPO financing round; Genetron Health closed the year’s largest single transaction in December, securing RMB 1 billion in Series B funding. Amidst this industry leap, what are the core values and key focal points of cancer early screening?
Guest:Master Zhu Shida| Commander-in-Chief of BGI’s “Fire Eye” Laboratories in China, Director of BGI’s R&D Center, and Head of the Oncology Business Unit
Topic: Technological Developments and Innovative Directions in Early Cancer Screening
HeAs the overall commander of the “Fire Eye” laboratories in China, he was dispatched to the front lines in Wuhan, where he led his team to establish the high-throughput, automated, next-generation nucleic acid testing facility—Wuhan’s “Fire Eye” Laboratory—within one week, and subsequently replicated the “Fire Eye” model globally. In September 2020, he was honored as an Advanced Individual in China’s Fight Against the COVID-19 Epidemic. At the 5th Future Healthcare Top 100 Conference, he will share insights on the future technological advancements and innovative developments in early cancer screening.
Guest:Wang Shiwei|VCBeat. Researcher
Topic: The Emergence of Giants and Product Upgrades—2021 Industry Report on Early Cancer Screening
In recent years, China’s early cancer screening sector has achieved its most rapid development in history. In a sense, the technical capabilities of domestic early cancer screening companies have caught up with, and even surpassed, those of leading global enterprises. Based solely on published data, the early screening products from New Horizon Health, Genetron Health, and Huirui Gene have all reached at least comparable levels of sensitivity and specificity to their overseas counterparts. As industry giants emerge and products undergo upgrades, what path lies ahead for early cancer screening?
Guest:Zhou Jun| CEO of Herui Genomics
Topic: China's Early Cancer Screening Program Based on HIFI Technology
In February, clinical research findings on the HIFI technology for early cancer screening were published in Cell Research, an internationally authoritative journal with an impact factor of 20.5. The authoritative publication of this study fully demonstrates that HIFI technology holds significant academic importance, clinical value, and application prospects in the field of genetic testing for early cancer screening. In August 2020, New Horizon Health launched its first liver cancer early screening product based on HIFI technology, “Laisining.”How to Leverage HIFI Technology to Successfully Replicate Liver Cancer Products Across Other Major Cancer Types, Including Lung Cancer?
Guest:Zhang Lianglu| Founder and General Manager of Amison
Topic Direction:Application of DNA Methylation Detection Technology in Tumor Early Screening Products
The COVID-19 pandemic has altered the trajectory of human societal development, leading to a widespread and significant increase in health awareness among the general public. The concept of molecular testing has become widely recognized and deeply ingrained, with growing numbers of people paying attention to early cancer screening and understanding its significance. Driven by advances in technology, supportive policies, capital investment, market dynamics, and shifts in public perception, the early cancer screening industry has emerged as one of the hottest areas for biomedical entrepreneurship both domestically and internationally. How can technological and product innovations enable screening to reach households across the nation?
Guest:Yan Linghua| CEO of TreeGenes
Topic: Business Exploration from Diagnostic Testing to Early Screening
As a rising star in the field of oncology genetic testing, Tree Gene has carved out a distinctive development path. How can it win customer acclaim amidst fierce market competition while achieving substantive in-house testing implementation across dozens of hospitals, expanding from diagnostic testing to early screening?
Guest:Chen Gang|Founder and CEO of Kanglu Biotech
Topic: Early Screening and Prognostic Diagnosis of Bladder Cancer
Social surveys and medical statistics from both China and abroad indicate that an increasing number of diseases have been confirmed to pose serious threats to men’s physical and mental health. In 2015, there were approximately 60,300 new cases of prostate cancer in China, with about 26,600 deaths, ranking it as the second most common malignant tumor of the urinary system. Undoubtedly, bladder cancer and prostate cancer have become the “two major killers” of the urinary system.
Guest:
Chen Zanquan|CEO/Co-founder of Zaoshai.com
Shen Qin| Managing Partner, Shengyu Investment Management
Zhu Shida| Director-General of BGI’s “Fire Eye Laboratory” in China, Director of BGI Genomics R&D Center, and Head of the Oncology Business Unit
Jiang Tang|Senior Vice President and Chief Strategy Officer of Dian Diagnostics
Zhu Ruixin| Vice President of Bioinformatics, Rendo Medical Group
Yan Linghua|CEO of Tongsu Gene
Topic: New Opportunities in the Blue Ocean Market for Early Cancer Screening
In 2020, the cancer early screening market experienced leapfrog development. Multiple companies, including New Horizon Health, ClearMed Biotech, and Genetron Health, secured single-round financing exceeding RMB 100 million. Pan-Genomics and Burning Rock Biotech, both heavily invested in the cancer early screening sector, successfully listed on NASDAQ. Illumina acquired Grail for $8 billion, and China’s first Class III medical device certificate for genetic testing-based cancer early screening was issued. These significant events, concentrated in 2020, signal that cancer early screening has become an industry hotspot, transitioning from the R&D phase to product commercialization, with companies entering a harvest period. How should stakeholders seize the new opportunities in the blue ocean market of tumor early screening?
"Calculating Life": The 5th Future Healthcare Top 100 Conference
April 16–18, 2021, VCBeat will join forces withPeople's Government of Wujiang District, Suzhou City、Guangdong Zhong Nanshan Medical Foundation、Suzhou Wujiang Dongfang State-owned Capital Investment and Operation Co., Ltd.InSuzhou · WujiangCo-hosting the 5th Future Healthcare Top 100 Conference. The conference will focus on the healthcare industry, with an emphasis on personal health, public health, the healthcare industry chain, and supporting infrastructure systems. For the first time, the conference will explore the industrial ecosystem, linking more possibilities in healthcare and achieving a comprehensive upgrade of the Top 100 Conference.
>>>>Confirmed Guests (Partial)
Fan Jia|Academician of the Chinese Academy of Sciences, President of Zhongshan Hospital, Fudan University
Zhang Zhiyuan| Academician of the Chinese Academy of Engineering
Shiqing Chen| Member of the U.S. National Academy of Engineering, Supercomputing Expert
Li Changming| Dean of the School of Materials Science and Engineering, Suzhou University of Science and Technology; Academician of Academia Europaea
Timothy Johns | Digital Health Officer, British Consulate-General in Shanghai
Song Yijun| Representative of the Government of Ontario, Canada; Commercial Counsellor, Canadian Embassy in China
Sun Baoqing| Chairman of the Guangdong Zhong Nanshan Medical Foundation
Nick Rodgers| Chairman of the South East Academic Health System for Technology, Chairman of Destiny Pharma
Wang Tianmiao| Professor at Beihang University
Wang Jingjing| Executive Director, Global Health Industry Innovation Center, Tsinghua University
Jane Jin | Head of Oxford University's Technology Transfer Office, China Region
Zhi Zhang | Business Development Manager, Technology Division, UK Medical Research Council |
Chen Fangxia| Director of Business Development, Asia Technology Transfer Center, Western University, Canada
Kimon Angelides | Founder, Livongo & Vivante
Luo Zhangwei| Chief Scientist, Suzhou Smart Healthcare Innovation Center; Former Chief AI Scientist, Siemens China Research Institute, Suzhou Branch
Liu Enmei| Deputy Director, Children's Hospital of Chongqing Medical University (Liangjiang Campus)
Chen Hongxiang| Executive Vice President, Union Shenzhen Hospital of Huazhong University of Science and Technology (Nanshan Hospital)
Tao Liang| President of Wuhan Asia Heart Hospital
Zhang Nuofu| Vice President of the First Affiliated Hospital of Guangzhou Medical University
Weng Jianping| Deputy Director of the Division of Life Sciences and Medicine, University of Science and Technology of China; President of Bengbu Medical College
Lei Juan| Deputy Director of the West China Transfer Center, West China Hospital, Sichuan University
Wei Xuejie| Vice President of Xuzhou Mining Group General Hospital
Ye Xin| Deputy Director, Yilianzhong Beijing Research Institute
Wu Xia| Managing Director, CICC Capital
Zhang Man| Vice President, China Renaissance
Wang Xiaohui| Managing Partner, Shengjing Jiacheng Fund of Funds
Hu Chuanwei| Vice President, Hengqin JinTou Group
Li Yuhui| Founding Managing Partner, Panlin Capital
Yu Zhengkun| Founding Partner, Jifeng Capital
Zhou Yi| Partner, Shenzhen Capital Group Health Industry Fund
Tian Min| Partner, Yuanjing Capital
Tang Haofu| Chairman of Chuangrui Investment
Ren Bobing| Executive Director, Sinovation Ventures
Andrew Craig| WG Fund Partner
……
>>>>Conference Highlights
Top-Tier Guest Lineup—Led by Academicians and IEEE Scientists200+Leading Experts Present Three Days of Cutting-Edge Medical Technology, Industry Trends, and Business Innovation
Business Wisdom of Industry Leaders—10Major Benchmark Listed Companies Unveil Strategic Roadmaps, Offering Insights into the Industry’s Future and Innovation Landscape
Global Perspective and Overseas Resources—FromUnited Kingdom, Israel, United States, Canada, Belgium, Germany, Denmarkand the industrial development trends and capital markets of multiple countries, linking high-quality overseas technological innovation projects
In-Depth Insights into Niche Sectors—Major Release10 copiesIndustry Research Series: Exploring Development Opportunities and Innovative Cases in Niche Sectors
Gathering the Core Forces of Future Healthcare – Release6 MajorTop 100 Lists and Awards, Converged1000+Unicorns and High-Potential Innovative Enterprises Explore Pathways for Innovation-Driven Development
Emphasizing the Translation of Scientific Research Achievements – Invitation10+Hospital Presidents, Research Experts, and University Scholars: Breaking Boundaries to Explore the Integration of Industry and Research
A Forward-Looking Capital Perspective—100+Featuring forward-looking investors from GP, LP, CVC, VC, PE, FA, and other financial institutions to gauge the direction of capital heat in the industry.
Harnessing the Momentum of the Industrial Ecosystem——10+Ecosystem Conference for Investment Firms and Industry Giants: Driving Integration and Exponential Growth in the Industrial Ecosystem
Click the link or scan the QR code to view conference details and purchase tickets.